Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2025)
Historic Accumulated Expenses for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $18.4 million.
- Denali Therapeutics' Accumulated Expenses rose 2342.34% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 2342.34%. This contributed to the annual value of $24.7 million for FY2024, which is 6390.02% down from last year.
- Latest data reveals that Denali Therapeutics reported Accumulated Expenses of $18.4 million as of Q3 2025, which was up 2342.34% from $12.1 million recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Accumulated Expenses peaked at $68.5 million during Q4 2023, and registered a low of $5.8 million during Q1 2022.
- Over the past 5 years, Denali Therapeutics' median Accumulated Expenses value was $10.5 million (recorded in 2021), while the average stood at $17.7 million.
- In the last 5 years, Denali Therapeutics' Accumulated Expenses soared by 25076.53% in 2022 and then plummeted by 6390.02% in 2024.
- Over the past 5 years, Denali Therapeutics' Accumulated Expenses (Quarter) stood at $19.0 million in 2021, then soared by 250.77% to $66.7 million in 2022, then grew by 2.71% to $68.5 million in 2023, then tumbled by 63.9% to $24.7 million in 2024, then fell by 25.76% to $18.4 million in 2025.
- Its Accumulated Expenses stands at $18.4 million for Q3 2025, versus $12.1 million for Q2 2025 and $7.7 million for Q1 2025.